Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2434-2437

  Sader, Helio S ^a   Rhomberg, Paul R ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; TAZOBACTAM;

ARTICLE; BACTERIAL COUNT; BIOASSAY; CONTROLLED STUDY; DRUG EXPOSURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; TIME KILL ASSAY;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; ESCHERICHIA COLI; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 84896990706     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02398-13     Document Type: Article

References (17)

1. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob. Agents Chemother. 57:6305-6310. http://dx.doi.org/10. 1128/AAC.01802-13.
2. MacKenzie FM, Gould IM. 1993. The post-antibiotic effect. J. Antimicrob. Chemother. 32:519-537. http://dx.doi.org/10.1093/jac/32.4.519. (Pubitemid 23324845)
3. Lavigne JP, Bonnet R, Michaux-Charachon S, Jourdan J, Caillon J, Sotto A. 2004. Post-antibiotic and post-β-lactamase inhibitor effects of ceftazidime plus sulbactam on extended-spectrum β-lactamase-producing Gram-negative bacteria. J. Antimicrob. Chemother. 53:616-619. http://dx.doi.org/10.1093/jac/dkh140. (Pubitemid 38499776)
4. Murbach V, Dhoyen N, Linger L, Monteil H, Jehl F. 2001. Evidence for a true post-β-lactamase-inhibitor effect of clavulanic acid against Klebsiella pneumoniae and Haemophilus influenzae. Clin. Microbiol. Infect. 7:661-665. http://dx.doi.org/10.1046/j.1469-0691.2001.00336.x. (Pubitemid 34960368)
5. Thorburn CE, Molesworth SJ, Sutherland R, Rittenhouse S. 1996. Postantibiotic and post-beta-lactamase inhibitor effects of amoxicillin plus clavulanate. Antimicrob. Agents Chemother. 40:2796-2801. (Pubitemid 26404346)
6. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
7. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob. Agents Chemother. 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.
8. Sader HS, Rhomberg RN, Jones RN. 2013. Post β-lactamase inhibitor effect of tazobactam when associated with ceftolozane and tested against ESBL-producing strains, poster A-1030. 53rd Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
9. Clinical and Laboratory Standards Institute. 2006. M26-A. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2012. M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard, 9th ed. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
12. Craig WA. 1993. Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J. Antimicrob. Chemother. 31(Suppl D):149-158. http://dx.doi.org/10.1093/jac/31. suppl-D.149. (Pubitemid 23193761)
13. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298. http://dx.doi.org/10.1093/infdis/157.2.287. (Pubitemid 18061241)
14. Fantin B, Leggett J, Ebert S, Craig WA. 1991. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob. Agents Chemother. 35: 1413-1422. http://dx.doi.org/10.1128/AAC.35.7.1413.
15. Vanscoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob. Agents Chemother. 57:5924-5930. http://dx.doi.org/10.1128/AAC.00656-13.
16. Castanheira M, Farrell SE, Deshpande LM, Mendes RE, Jones RN. 2013. Prevalence of β-lactamase encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U. S. A. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010). Antimicrob. Agents Chemother. 57:3012-3020. http://dx.doi.org/10.1128/AAC.02252-12.
17. Bush K. 2013. Proliferation and significance of clinically relevant betalactamases. Ann. N. Y. Acad. Sci. 1277:84-90. http://dx.doi.org/10.1111/ nyas.12023.